KRAS and lung adenocarcinoma: The comutations with KRAS were reported to be the primary drivers of molecular and immunological differences in KRAS-mutant lung adenocarcinomas, while specific KRAS mutations (KRASG12C, KRASG12V, KRASG12D, and others) did not have a consistent pattern [37].